Drugs

, Volume 66, Issue 13, pp 1685–1700

Pharmacological Treatments for Thyroid Eye Disease

  • Sara P. Modjtahedi
  • Bobeck S. Modjtahedi
  • Ahmad M. Mansury
  • Dinesh Selva
  • Raymond S. Douglas
  • Robert A. Goldberg
  • Igal Leibovitch
Therapy In Practice

Abstract

Thyroid eye disease (TED), which affects the majority of patients with Grave’s disease, is associated with significant ophthalmic morbidity. In patients with mild disease, supportive treatment with lubricating medication can be sufficient. However, in patients with severe TED and disfiguring proptosis or sight-threatening neuropathy, more aggressive medical or surgical interventions are necessary. Corticosteroids remain the preferred pharmacological treatment modality in the majority of patients with an active inflammatory component. Other immunosuppressive drugs in combination with corticosteroids may be helpful in patients with corticosteroid-resistant TED. Newer agents such as somatostatin analogues have not shown to be of significant clinical benefit; however, initial studies on the use of antioxidants and cytokine antagonists are encouraging.

References

  1. 1.
    Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002 Oct; 12(10): 855–60PubMedCrossRefGoogle Scholar
  2. 2.
    Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Lab sci 2000 Dec; 37(6): 523–49PubMedCrossRefGoogle Scholar
  3. 3.
    Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves ophthalmopathy. Ophthal Plast Reconstr Surg 2002 Nov; 18(6): 402–8PubMedCrossRefGoogle Scholar
  4. 4.
    Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995 Jan; 42(1): 45–50CrossRefGoogle Scholar
  5. 5.
    El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 2004 Aug; 34(8): 482–91PubMedCrossRefGoogle Scholar
  6. 6.
    Bahn RS. Clinical review 157: pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003 May; 88(5): 1939–46PubMedCrossRefGoogle Scholar
  7. 7.
    Ludgate M, Baker G. Inducing Graves’ ophthalmopathy. J Endocrinol Invest 2004 Mar; 27(3): 211–5PubMedGoogle Scholar
  8. 8.
    McLachlan SM, Bahn R, Rapoport B. Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity 1992; 14(2): 143–8PubMedCrossRefGoogle Scholar
  9. 9.
    Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med 1993 Nov 11; 329(20): 1468–75PubMedCrossRefGoogle Scholar
  10. 10.
    Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004 Mar; 27(3): 295–301PubMedGoogle Scholar
  11. 11.
    de Carli M, D’Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves’ ophthalmopathy. J Clin Endocrinol Metab 1993 Nov; 77(5): 1120–4PubMedCrossRefGoogle Scholar
  12. 12.
    Campbell RJ. Pathology of Graves’ ophthalmopathy. In: Gorman CA, Waller RR, Dyer JA, editors. The eye and orbit in thyroid disease. New York: Raven Press, 1984: 25–31Google Scholar
  13. 13.
    Campbell RJ. Immunology of Graves’ ophthalmopathy: retrobulbar histology, histochemistry. Acta Endocrinol 1989; 121 Suppl. 2: 9–16Google Scholar
  14. 14.
    Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989 Aug; 10(3): 366–91PubMedCrossRefGoogle Scholar
  15. 15.
    Bahn RS, Heufelder AE. Retroocular fibroblasts: important effector cells in Graves’ ophthalmopathy. Thyroid 1992; 2(1): 89–94PubMedCrossRefGoogle Scholar
  16. 16.
    Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003 Dec; 24(6): 802–35PubMedCrossRefGoogle Scholar
  17. 17.
    Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994 Jan; 40(1): 67–72CrossRefGoogle Scholar
  18. 18.
    Gianoukakis AG, Douglas RS, King CS, et al. IgG from patients with Graves’ disease induces IL-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T cell infiltration of the thyroid in autoimmune disease. Endocrinology 2006 Apr; 147(4): 1941–9PubMedCrossRefGoogle Scholar
  19. 19.
    Sautter-Bihl ML. Orbital radiotherapy: recent experience in Europe. In: Wall JR, How J, editors. Graves’ ophthalmolpathy. Cambridge: Blackwell, 1990: 145–157Google Scholar
  20. 20.
    Bartalena L, Marcocci C, Manetti L, et al. Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 1998 May; 8(5): 439–41PubMedCrossRefGoogle Scholar
  21. 21.
    Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol 2004 Dec; 15(6): 479–82PubMedCrossRefGoogle Scholar
  22. 22.
    Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet 2000 Apr 29; 355(9214): 1505–9PubMedCrossRefGoogle Scholar
  23. 23.
    Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 2003 Aug; 88(8): 3561–6PubMedCrossRefGoogle Scholar
  24. 24.
    Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 2001 Sep; 108(9): 1523–34PubMedCrossRefGoogle Scholar
  25. 25.
    Goh MS, McNab AA. Orbital decompression in Graves’ orbitopathy: efficacy and safety. Intern Med J 2005 Oct; 35(10): 586–91PubMedCrossRefGoogle Scholar
  26. 26.
    Goldberg RA, Weinberg DA, Shorr N, et al. Maximal, three-wall, orbital decompression through a coronal approach. Ophthalmic Surg Lasers 1997 Oct; 28(10): 832–43PubMedGoogle Scholar
  27. 27.
    Kalmann R, Mourits MP, van der Pol JP, et al. Coronal approach for rehabilitative orbital decompression in Graves’ ophthalmopathy. Br J Ophthalmol 1997 Jan; 81(1): 41–5PubMedCrossRefGoogle Scholar
  28. 28.
    Ulualp SO, Massaro BM, Toohill RJ. Course of proptosis in patients with Graves’ disease after endoscopic orbital decompression. Laryngoscope 1999 Aug; 109(8): 1217–22PubMedCrossRefGoogle Scholar
  29. 29.
    Goldberg RA, Shorr N, Cohen MS. The medical orbital strut in the prevention of postdecompression dystopia in dysthyroid ophthalmopathy. Ophthal Plast Reconstr Surg 1992; 8(1): 32–4PubMedCrossRefGoogle Scholar
  30. 30.
    Wiersinga WM, Smit T, Schuster-Uittenhoeve AL, et al. Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves’ ophthalmopathy. Ophthalmologica 1988; 197(2): 75–84PubMedCrossRefGoogle Scholar
  31. 31.
    Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000 Apr; 21(2): 168–99PubMedCrossRefGoogle Scholar
  32. 32.
    Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves’ ophthalmopathy on quality of life. J Endocrinol Invest 2004 Mar; 27(3): 259–64PubMedGoogle Scholar
  33. 33.
    Wiersinga WM. Immunosuppressive treatment of Graves’ ophthalmopathy. Thyroid 1992; 2(3): 229–33PubMedCrossRefGoogle Scholar
  34. 34.
    Brauer VF, Scholz GH. Treatment of Graves’ ophthalmopathy with oral or intravenous corticosteroids. Med Klin 2004 Feb 15; 99(2): 71–6CrossRefGoogle Scholar
  35. 35.
    Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001 Aug; 86(8): 3562–7PubMedCrossRefGoogle Scholar
  36. 36.
    Ohtsuka K, Sato A, Kawaguchi S, et al. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy. Am J Ophthalmol 2003 Mar; 135(3): 285–90PubMedCrossRefGoogle Scholar
  37. 37.
    Koshiyama H, Koh T, Fujiwara K, et al. Therapy of Graves’ ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation. Thyroid 1994; 4(4): 409–13PubMedCrossRefGoogle Scholar
  38. 38.
    Kendall-Taylor P, Crombie AL, Stephenson AM, et al. Intravenous methylprednisolone in the treatment of Graves’ ophthalmopathy. BMJ 1988 Dec 17; 297(6663): 1574–8PubMedCrossRefGoogle Scholar
  39. 39.
    Hiromatsu Y, Tanaka K, Sato M, et al. Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J 1993 Feb; 40(1): 63–72PubMedCrossRefGoogle Scholar
  40. 40.
    Matejka G, Verges B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves’ ophthalmopathy. Horm Metab Res 1998 Feb; 30(2): 93–8PubMedCrossRefGoogle Scholar
  41. 41.
    Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 2005 Sep; 90(9): 5234–40PubMedCrossRefGoogle Scholar
  42. 42.
    Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest 2001 Mar; 24(3): 152–8PubMedGoogle Scholar
  43. 43.
    Hart RH, Kendall-Taylor P, Crombie A, et al. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 2005 Aug; 21(4): 328–36PubMedCrossRefGoogle Scholar
  44. 44.
    Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005 Sep; 63(3): 323–8CrossRefGoogle Scholar
  45. 45.
    Marino M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 2004; 14: 403–6PubMedCrossRefGoogle Scholar
  46. 46.
    Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004 Nov; 88(11): 1380–6PubMedCrossRefGoogle Scholar
  47. 47.
    Poonyathalang A, Preechawat P, Charoenkul W, et al. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai 2005 Mar; 88(3): 345–9PubMedGoogle Scholar
  48. 48.
    Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 1987 Jul; 27(1): 33–42CrossRefGoogle Scholar
  49. 49.
    Pinchera A, Marcocci C, Bartalena L, et al. Orbital cobalt radiotherapy and systemic or retrobulbar corticosteroids for Graves’ ophthalmopathy. Horm Res 1987; 26(1–4): 177–83PubMedCrossRefGoogle Scholar
  50. 50.
    Thomas ID, Hart JK. Retrobulbar repository corticosteroid therapy in thyroid ophthalmopathy. Med J Aust 1974 Sep 28; 2(13): 484–7PubMedGoogle Scholar
  51. 51.
    Ivy HK. Medical approach to ophthalmopathy of Graves’ disease. Mayo Clin Proc 1972 Dec; 47(12): 980–5PubMedGoogle Scholar
  52. 52.
    Garber MI. Methylprednisolone in the treatment of exophthalmos. Lancet 1966 Apr 30; 1(7444): 958–60PubMedCrossRefGoogle Scholar
  53. 53.
    Gebertt S. Depot-methylprednisolone for subconjunctival and retrobulbar injections. Lancet 1961 Aug 12; 2: 344–5PubMedCrossRefGoogle Scholar
  54. 54.
    Goldberg RA. Orbital steroid injections. Br J Ophthalmol 2004 Nov; 88(11): 1359–60PubMedCrossRefGoogle Scholar
  55. 55.
    Giles CL. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol 1974 Apr; 77(4): 438–41PubMedGoogle Scholar
  56. 56.
    Schlaegel TF, Wilson FM. Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 847–55Google Scholar
  57. 57.
    Hosal BM, Zilelioglu G. Ocular complication of intralesional corticosteroid injection of a chalazion. Eur J Ophthalmol 2003 Nov–Dec; 13(9–10): 798–9PubMedGoogle Scholar
  58. 58.
    Jabs DA. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis [discussion by Dr A Jabs]. Ophthalmology 2002; 109: 806–7CrossRefGoogle Scholar
  59. 59.
    Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 2003 Sep; 136(3): 539–40PubMedCrossRefGoogle Scholar
  60. 60.
    Fogla R, Rao SK, Biswas J. Avoiding conjunctival necrosis after periocular depot corticosteroid injection. J Cataract Refract Surg 2000 Feb; 26(2): 163–4PubMedCrossRefGoogle Scholar
  61. 61.
    Moshfeghi DM, Lowder CY, Roth DB, et al. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 2002 Jul; 134(1): 132–4PubMedCrossRefGoogle Scholar
  62. 62.
    Ellis PP. Occlusion of the central retinal artery after retrobulbar corticosteroid injection. Am J Ophthalmol 1978 Mar; 85(3): 352–6PubMedGoogle Scholar
  63. 63.
    Shorr N, sciff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986 Apr; 17(4): 229–31PubMedGoogle Scholar
  64. 64.
    Mabry RL. Visual loss after intranasal corticosteroid injection. Incidence, causes, and prevention. Arch Otolaryngol 1981 Aug; 107(8): 484–6CrossRefGoogle Scholar
  65. 65.
    McGrew RN, Wilson RS, Havener WH. Sudden blindness secondary to injections of common drugs in the head and neck: I. clinical experiences. Otolaryngology 1978 Jan–Feb; 86(1): ORL-147–51Google Scholar
  66. 66.
    McCleve DE, Goldstein JC. Blindness secondary to injections in the nose, mouth, and face: cause and prevention. Ear Nose Throat J 1995 Mar; 74(3): 182–8PubMedGoogle Scholar
  67. 67.
    McLean EB. Inadvertent injection of corticosteroid into the choroidal vasculature. Am J Ophthalmol 1975 Nov; 80(5): 835–7PubMedGoogle Scholar
  68. 68.
    Thomas EL, Laborde RP. Retinal and choroidal vascular occlusion following intralesional corticosteroid injection of a chalazion. Ophthalmology 1986 Mar; 93(3): 405–7PubMedGoogle Scholar
  69. 69.
    Gupta OP, Boynton JR, Sabini P, et al. Proptosis after retrobulbar corticosteroid injections. Ophthalmology 2003 Feb; 110(2): 443–7PubMedCrossRefGoogle Scholar
  70. 70.
    Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection. Am J Ophthalmol 1976 Dec; 82(6): 928–30PubMedGoogle Scholar
  71. 71.
    Smith JR, George RK, Rosenbaum JT. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am J Ophthalmol 2002 Jun; 133(6): 845–7PubMedCrossRefGoogle Scholar
  72. 72.
    Herschier J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 1972 Sep; 74(3): 501–4Google Scholar
  73. 73.
    Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of prospective randomized study. J Endocrinol Invest 1991; 14: 853–60PubMedGoogle Scholar
  74. 74.
    Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56: 1139–44PubMedCrossRefGoogle Scholar
  75. 75.
    Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998 Jan 8; 338: 73–8PubMedCrossRefGoogle Scholar
  76. 76.
    Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001 Apr; 144(4): 311–8PubMedCrossRefGoogle Scholar
  77. 77.
    Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone vs prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986 Oct; 16(5): 415–22PubMedCrossRefGoogle Scholar
  78. 78.
    Leovey A, Bako G, Szabo J, et al. Combined cyclosporin-A and methylprednisolone treatment of Graves’ ophthalmopathy. Acta Med Hung 1992-93; 49(3–4): 179–85Google Scholar
  79. 79.
    Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 1989 Nov 16; 321(20): 1353–9PubMedCrossRefGoogle Scholar
  80. 80.
    Bahn RS. Understanding the immunology of Graves’ ophthalmopathy: is it an autoimmune disease? Endocrinol Metab Clin North Am 2000 Jun; 29(2): 287–96PubMedCrossRefGoogle Scholar
  81. 81.
    Heufelder AE, Schworm HD, Heufelder G. Methotrexate in the treatment of refractory Graves’ ophthalmopathy [abstract no. O-002]. 12th International Thyroid Congress; 2000 Oct 22–27; Kyoto, JapanGoogle Scholar
  82. 82.
    Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001 Oct; 85(10): 1220–4PubMedCrossRefGoogle Scholar
  83. 83.
    Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves’ ophthalmopathy: do they bounce off like a rubber bullet? J Clin Endocrinol Metab 2004 Dec; 89(12): 5908–9PubMedCrossRefGoogle Scholar
  84. 84.
    Krassas GE. Somatostatin analogs: a new tool for the management of Graves’ ophthalmopathy. J Endocrinol Invest 2004 Mar; 27(3): 281–7PubMedGoogle Scholar
  85. 85.
    Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005 Feb; 90(2): 841–8PubMedCrossRefGoogle Scholar
  86. 86.
    Wiersinga WM, Prummel MF, Mourits MP, et al. Classification of eyesigns of Graves. Thyroid 1991; 1(4): 357–60PubMedCrossRefGoogle Scholar
  87. 87.
    Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639–44PubMedCrossRefGoogle Scholar
  88. 88.
    Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004 Dec; 89(12): 5910–5PubMedCrossRefGoogle Scholar
  89. 89.
    Pasquali D, Notaro A, Bonavolonta’ G, et al. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab 2002 Nov; 87(11): 5125–9PubMedCrossRefGoogle Scholar
  90. 90.
    Pasquali D, Vassallo P, Esposito D, et al. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol 2000 Aug; 25(1): 63–71PubMedCrossRefGoogle Scholar
  91. 91.
    Saveanu A, Gunz G, Dufour H, et al. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest 2003; 26 (8 Suppl.): 4–7PubMedGoogle Scholar
  92. 92.
    Boerlin V, van der Hoek J, Beglinger CH, et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003; 26 (8 Suppl.): 14–6PubMedGoogle Scholar
  93. 93.
    Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002 May; 146(5): 707–16PubMedCrossRefGoogle Scholar
  94. 94.
    Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J Endocrinol Invest 2004 Mar; 27(3): 265–71PubMedGoogle Scholar
  95. 95.
    Shine B, Fells P, Edwards OM, et al. Association between Graves’ ophthalmopathy and smoking. Lancet 1990 May 26; 335(8700): 1261–3PubMedCrossRefGoogle Scholar
  96. 96.
    Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking? BMJ (Clin Res Ed) 1987 Sep 12; 295(6599): 634–5CrossRefGoogle Scholar
  97. 97.
    Bouzas EA, Karadimas P, Mastorakos G, et al. Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol 2000 May; 129(5): 618–22PubMedCrossRefGoogle Scholar
  98. 98.
    Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves’ ophthalmopathy patients. Thyroid 1999 Mar; 9(3): 297–303PubMedCrossRefGoogle Scholar
  99. 99.
    Heufelder AE, Wenzel BE, Bahn RS. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts. J Clin Endocrinol Metab 1992 Apr; 74(4): 737–42PubMedCrossRefGoogle Scholar
  100. 100.
    Burch HB, Lahiri S, Bahn RS, et al. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp Eye Res 1997 Aug; 65(2): 311–6PubMedCrossRefGoogle Scholar
  101. 101.
    Bartalena L, Tanda ML, Piantanida E, et al. Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003; 19(3–4): 155–63PubMedCrossRefGoogle Scholar
  102. 102.
    Balazs C, Kiss E, Vamos A, et al. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study [published erratum appears in J Clin Endocrinol Metab 1997 Sep; 82 (9): 3077]. J Clin Endocrinol Metab 1997 Jun; 82(6): 1999–2002PubMedGoogle Scholar
  103. 103.
    Finamor FE, Martins JR, Nakanami D, et al. Pentoxifylline (PTX): an alternative treatment in Graves’ ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur J Ophthalmol 2004 Jul–Aug; 14(4): 277–83PubMedGoogle Scholar
  104. 104.
    Krassas GE, Pontikides N, Doukidis D, et al. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. Thyroid 2001 Dec; 11(12): 1115–22PubMedCrossRefGoogle Scholar
  105. 105.
    Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye 2005 Dec; 19(12): 1286–9PubMedCrossRefGoogle Scholar
  106. 106.
    Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005 Jun; 24(2): 117–9PubMedCrossRefGoogle Scholar
  107. 107.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340(4): 253–9PubMedCrossRefGoogle Scholar
  108. 108.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337(3): 141–7PubMedCrossRefGoogle Scholar
  109. 109.
    Bartalena L. Editorial: glucocorticoids for Graves’ ophthalmopathy: how and when. J Clin Endocrinol Metab 2005 Sep; 90(9): 5497–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Sara P. Modjtahedi
    • 1
    • 3
  • Bobeck S. Modjtahedi
    • 1
    • 3
  • Ahmad M. Mansury
    • 1
    • 3
  • Dinesh Selva
    • 2
    • 3
  • Raymond S. Douglas
    • 1
    • 3
  • Robert A. Goldberg
    • 1
    • 3
  • Igal Leibovitch
    • 1
    • 3
  1. 1.Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye InstituteLos AngelesUSA
  2. 2.Oculoplastic and Orbital Division, Department of Ophthalmology and Visual Sciences, Royal Adelaide HospitalUniversity of AdelaideAdelaideAustralia
  3. 3.Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of CaliforniaLos AngelesUSA

Personalised recommendations